Related Experiment Videos
Summary
Elevated alkaline phosphatase in rheumatoid arthritis patients often indicates liver damage from antirheumatic drugs. Monitoring liver enzymes like alkaline phosphatase and gamma-GT during treatment is crucial for patient safety.
Area of Science:
- Hepatology
- Rheumatology
- Clinical Chemistry
Background:
- Rheumatoid arthritis (RA) management often involves long-term antirheumatic drug use.
- Non-steroidal anti-rheumatic drugs (NSAIDs) are commonly prescribed for RA symptom relief.
- Potential hepatotoxicity is a known concern with certain antirheumatic medications.
Purpose of the Study:
- To investigate the prevalence of elevated alkaline phosphatase in RA patients.
- To identify the source of elevated alkaline phosphatase, specifically hepatic involvement.
- To assess the relationship between antirheumatic therapy and potential liver damage.
Main Methods:
- Analysis of alkaline serum phosphatase activity in 161 rheumatoid arthritis patients.
- Heat inactivation tests to identify hepatic phosphatase.
- Polyacrylamide gel electrophoresis for isoenzyme determination.
Main Results:
- 37.3% of RA patients exhibited raised alkaline serum phosphatase activity.
- Elevated levels were confirmed as hepatic phosphatase through laboratory analyses.
- Findings suggest a link between antirheumatic drugs and drug-induced cholestasis or toxic hepatic damage.
Conclusions:
- Elevated alkaline phosphatase is a frequent finding in RA patients undergoing treatment.
- Antirheumatic drugs, particularly NSAIDs, may cause hepatotoxicity and cholestasis.
- Regular monitoring of alkaline phosphatase and gamma-glutamyl transferase (gamma-GT) is recommended before and during RA treatment.